Trial · NCT05875961
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
NCT05875961, Phase 1, Completed, Seqirus
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults. Trials, record NCT05875961. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05875961
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
- NCT number
- NCT05875961
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 600 participants, actual
- Lead sponsor
- Seqirus
- Conditions
- Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
- Interventions
Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59
- First posted
- 2023-05-25
- Last updated
- 2026-09-21
Source ClinicalTrials.gov
Registered outcomes54
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Geometric mean titer (GMT) of hemagglutination inhibition (HI) antibodies against homologous H2N3 strain - Day 1 | Day 1 | GMT (HI) prevaccination |
| Primary | GMT of HI antibodies against homologous H2N3 strain - Day 8 | Day 8 | GMT (HI) 1 week postvaccination 1 |
| Primary | GMT of HI antibodies against homologous H2N3 strain Day 22 | Day 22 | GMT (HI) 3 weeks postvaccination 1 |
| Primary | GMT of HI antibodies against homologous H2N3 strain - Day 29 | Day 29 | GMT (HI) 1 week postvaccination 2 |
| Primary | GMT of HI antibodies against homologous H2N3 strain - Day 43 | Day 43 | GMT (HI) 3 weeks postvaccination 2 |
| Primary | GMT of microneutralization (MN) antibodies against homologous H2N3 strain - Day 1 | Day 1 | GMT (MN) prevaccination |
| Primary | GMT of MN antibodies against homologous H2N3 strain - Day 8 | Day 8 | GMT (MN) 1 week postvaccination 1 |
| Primary | GMT of MN antibodies against homologous H2N3 strain - Day 22 | Day 22 | GMT (MN) 3 weeks postvaccination 1 |
| Primary | GMT of MN antibodies against homologous H2N3 strain - Day 29 | Day 29 | GMT (MN) 1 week postvaccination 2 |
| Primary | GMT of MN antibodies against homologous H2N3 strain - Day 43 | Day 43 | GMT (MN) 3 weeks postvaccination 2 |
1 to 10 of 54Source ClinicalTrials.gov
See all 54 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05875961
GET https://conductscience.org/api/trials/v1/NCT05875961/registered?page=2